Asset
Mipletamig
Aptevo Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06634394 | phase1 | recruiting | 2024-10-01 | 2027-10-01 | Aptevo Therapeutics | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML |
| NCT04973618 | phase1 | withdrawn | 2025-01-01 | 2026-01-01 | Aptevo Therapeutics | Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML |
FDA applications (0)
This company has no applications containing this asset.